Holmes S J
Center for Pediatric Research, Children's Hospital of the King's Daughters, Eastern Virginia Medical School, Norfolk, USA.
J Infect Dis. 1996 Nov;174 Suppl 3:S342-4. doi: 10.1093/infdis/174.supplement_3.s342.
After US licensure of the Merck varicella vaccine for immunocompetent persons on 17 March 1995, the Advisory Committee on Immunization Practices finalized draft recommendations for varicella prevention in the public health sector. These recommendations call for routine vaccination of children at age 12-18 months with a single dose of the vaccine. Varicella vaccine preferably should be given to children at the same time they receive measles-mumps-rubella vaccine and may be given at the same time as other vaccines recommended at this age. Children ages 18 months to 12 years who have not been vaccinated as part of the routine schedule and who lack a reliable history of varicella should be vaccinated. Vaccination is desirable for persons > or = 13 years old without a reliable history of varicella. Special efforts should be made to assess the immunity of and to vaccinate susceptible persons who have close contact with persons at high risk for complications, including family contacts of immunocompromised individuals and health care workers.
1995年3月17日默克水痘疫苗在美国获得免疫功能正常人群的许可后,免疫实践咨询委员会最终确定了公共卫生部门预防水痘的建议草案。这些建议要求对12至18个月大的儿童常规接种一剂该疫苗。水痘疫苗最好在儿童接种麻疹-腮腺炎-风疹疫苗的同时接种,也可与该年龄段推荐的其他疫苗同时接种。18个月至12岁未按常规程序接种且无可靠水痘病史的儿童应接种疫苗。13岁及以上无可靠水痘病史的人群也建议接种。应特别努力评估与并发症高危人群密切接触的易感人群的免疫力并为其接种疫苗,包括免疫功能低下个体的家庭接触者和医护人员。